TP53 and B-cell chronic lymphocytic leukemia: In the clinical setting, the efficacy of venetoclax monotherapy in TP53-aberrant CLL was confirmed in a subsequent phase 2 trial (M13-982; NCT01889186) (Table 1), in which an ORR of 79.4% was documented amongst 107 patients with R/R CLL who carried del(17p) and had received ≥ 1 prior therapy [49].